Clinical efficiency of panavir in therapy of chronicle papillomavirus infections of cervix uteri

This research is devoted to determination of the clinical efficacy of Panavir in the combined therapy of the uterine cervix diseases associated with human papillomavirus (HPV). The article presents data of the complex examination of 59 patients. Patients with diagnosed 16th, 18th, 31st, 33rd types of HPV underwent destructive methods of treatment of the cervix followed by Panavir. The efficacy of Panavir was estimated by PCR in 3, 6 and 12 months from the beginning of treatment and it was 84,7%. Antiviral therapy permits to prevent recurrence of papillomavirus infection of the cervix uteri.